Oct 7, 2024, 15:53
Pembrolizumab vs. Observation in Muscle-Invasive Urothelial Carcinoma
Tres Uramigas shared on X:
“Sure! Here’s the post without the usernames:
AMBASSADOR: Phase III Ca Urothelial with muscle invasion post-cystectomy pembrolizumab 1 vs observation in New England Journal of Medicine, Andrea Apolo, Petros Grivas.
- Disease-Free Survival (DFS) benefit
- Independent of PD-L1 and nodal status
- Metastatic recurrences frequency in the control arm.”
Source: Tres Uramigas/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 30, 2024, 06:48
Dec 30, 2024, 06:41
Dec 30, 2024, 03:53
Dec 30, 2024, 03:44
Dec 30, 2024, 03:33
Dec 30, 2024, 00:55
Dec 30, 2024, 00:53
Dec 30, 2024, 00:51
Dec 30, 2024, 00:36
Dec 30, 2024, 00:31